Profound Medical Corp. (PROF)

NASDAQ: PROF · Real-Time Price · USD
4.030
+0.070 (1.77%)
At close: Sep 12, 2025, 4:00 PM EDT
4.040
+0.010 (0.25%)
After-hours: Sep 12, 2025, 4:00 PM EDT
1.77%
Market Cap119.48M
Revenue (ttm)11.84M
Net Income (ttm)-40.73M
Shares Out 30.05M
EPS (ttm)-1.48
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume61,898
Open4.030
Previous Close3.960
Day's Range4.030 - 4.030
52-Week Range3.760 - 9.170
Beta0.22
AnalystsStrong Buy
Price Target11.00 (+172.95%)
Earnings DateNov 6, 2025

About PROF

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. The company’s lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prosta... [Read more]

Sector Healthcare
CEO Arun Menawat
Employees 142
Stock Exchange NASDAQ
Ticker Symbol PROF
Full Company Profile

Financial Performance

In 2024, Profound Medical's revenue was $10.68 million, an increase of 48.35% compared to the previous year's $7.20 million. Losses were -$27.82 million, -1.79% less than in 2023.

Financial Statements

Analyst Summary

According to one analyst, the rating for PROF stock is "Strong Buy" and the 12-month stock price target is $11.0.

Price Target
$11.0
(172.95% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Profound Medical to Participate in Lake Street's 9th Annual Best Ideas Growth Conference

TORONTO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable...

15 days ago - GlobeNewsWire

Profound Medical: Smokes Is Everywhere, Initiate At Sell

I am initiating Profound Medical Corp. at a Sell rating with a fair value of $2.9 per share due to financial concerns. TULSA-PRO shows promise for BPH and localized prostate cancer, but long-term effi...

24 days ago - Seeking Alpha

Profound Medical Corp. (PROF) Q2 2025 Earnings Call Transcript

Profound Medical Corp. (NASDAQ:PROF) Q2 2025 Earnings Conference Call August 14, 2025 4:30 PM ET Company Participants Arun Swarup Menawat - Chairman of the Board & CEO Mathieu Burtnyk - President Ras...

Other symbols: PRN
4 weeks ago - Seeking Alpha

Profound Medical Announces Second Quarter 2025 Financial Results

TORONTO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable...

4 weeks ago - GlobeNewsWire

Profound Medical to Release Second Quarter 2025 Financial Results on August 14 – Conference Call to Follow

TORONTO, July 24, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable...

7 weeks ago - GlobeNewsWire

Profound Medical Annual General and Special Meeting of Shareholders Voting Results

TORONTO, May 14, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce the voting results from its Annual General and Special Me...

4 months ago - GlobeNewsWire

Profound Medical Corporation (PROF) Q1 2025 Earnings Conference Call Transcript

Profound Medical Corporation (NASDAQ:PROF) Q1 2025 - Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Stephen Kilmer - Head IR Rashed Dewan - CFO Dr. Mathieu Burtnyk - COO Tom Tam...

4 months ago - Seeking Alpha

Profound Medical to Participate in the 2025 Bloom Burton & Co. Healthcare Investor Conference

TORONTO, April 30, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizabl...

4 months ago - GlobeNewsWire

Initial Perioperative Data from CAPTAIN Randomized Trial Demonstrate MRI-Guided TULSA Provides Statistically Significant Improvement of Post-Operative Experience Vs. Robotic Radical Prostatectomy

– First Level 1 study comparing an emerging technology head-to-head with RP in men with prostate cancer – – TULSA had no blood loss and no overnight stay, along with reduced post-procedure pain, and m...

4 months ago - GlobeNewsWire

Profound Medical AUA 2025 Investor Event Agenda

TORONTO, April 15, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizabl...

5 months ago - GlobeNewsWire

Profound Medical Corp. (PROF) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

NEW YORK, NY / ACCESS Newswire / April 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Profound Medical Corp. ("Profound" or "the Company") (N...

5 months ago - Accesswire

PROF Investors Have Opportunity to Join Profound Medical Corp. Fraud Investigation with the Schall Law Firm

LOS ANGELES , April 8, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Profound Medical Cor...

5 months ago - PRNewsWire

Bronstein, Gewirtz & Grossman, LLC Encourages Profound Medical Corp. (PROF) Shareholders to Inquire about Securities Investigation

NEW YORK, NY / ACCESS Newswire / April 7, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Profound Medical Corp. ("Profound" or "the Company") (N...

5 months ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Is Investigating Profound Medical Corp. (PROF) And Encourages Shareholders to Connect

NEW YORK, NY / ACCESS Newswire / April 6, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Profound Medical Corp. ("Profound" or "the Company") (N...

5 months ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Profound Medical Corp. (PROF) And Encourages Shareholders to Reach Out

NEW YORK, NY / ACCESS Newswire / April 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Profound Medical Corp. ("Profound" or "the Company") (N...

5 months ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Profound Medical Corp. (PROF) and Encourages Investors to Learn More About the Investigation

NEW YORK, NY / ACCESS Newswire / April 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Profound Medical Corp. ("Profound" or "the Company") (N...

5 months ago - Accesswire

Profound Medical Corp. (PROF) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

NEW YORK, NY / ACCESS Newswire / April 2, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Profound Medical Corp. ("Profound" or "the Company") (N...

5 months ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Is Investigating Profound Medical Corp. (PROF) And Encourages Investors to Connect

NEW YORK, NY / ACCESS Newswire / April 1, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Profound Medical Corp. ("Profound" or "the Company") (N...

5 months ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Encourages Profound Medical Corp. (PROF) Stockholders to Inquire about Securities Investigation

NEW YORK, NY / ACCESS Newswire / March 31, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Profound Medical Corp. ("Profound" or "the Company") (...

5 months ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Profound Medical Corp. (PROF) and Encourages Stockholders to Learn More About the Investigation

NEW YORK, NY / ACCESS Newswire / March 28, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Profound Medical Corp. ("Profound" or "the Company") (...

6 months ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Encourages Profound Medical Corp. (PROF) Investors to Inquire about Securities Investigation

NEW YORK, NY / ACCESS Newswire / March 27, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Profound Medical Corp. ("Profound" or "the Company") (...

6 months ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Profound Medical Corp. (PROF) And Encourages Investors to Reach Out

NEW YORK, NY / ACCESS Newswire / March 26, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Profound Medical Corp. ("Profound" or "the Company") (...

6 months ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Profound Medical Corp. (PROF) And Encourages Stockholders to Reach Out

NEW YORK, NY / ACCESS Newswire / March 25, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Profound Medical Corp. ("Profound" or "the Company") (...

6 months ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Is Investigating Profound Medical Corp. (PROF) And Encourages Stockholders to Connect

NEW YORK, NY / ACCESS Newswire / March 24, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Profound Medical Corp. ("Profound" or "the Company") (...

6 months ago - Accesswire